Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials

被引:205
作者
Antoniades, Charalambos [1 ]
Antonopoulos, Alexios S. [1 ]
Tousoulis, Dimitris [1 ]
Marinou, Kyriakoula [1 ]
Stefanadis, Christodoulos [1 ]
机构
[1] Univ Athens, Sch Med, Cardiol Dept 1, Athens 15344, Greece
关键词
NITRIC-OXIDE SYNTHASE; FACTOR-KAPPA-B; IMPAIRS ENDOTHELIAL FUNCTION; CAROTID-ARTERY STIFFNESS; FOLIC-ACID FORTIFICATION; SMOOTH-MUSCLE-CELLS; PLASMA HOMOCYSTEINE; RISK-FACTOR; CARDIOVASCULAR-DISEASE; VASCULAR-DISEASE;
D O I
10.1093/eurheartj/ehn515
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Plasma total homocysteine (Hcy) has been associated with cardiovascular risk in multiple large-scale epidemiological studies, and it has been considered as an independent risk factor for atherosclerosis. Homocysteine lowering, achieved after the introduction of the folate food fortification programme in North America, was accompanied by an accelerated decline of cardiovascular risk and especially of stroke. Although the initial clinical trials suggested that homocysteine-lowering treatment with folates and B vitamins induces coronary plaque regression, this finding was not confirmed by more recent clinical studies. Under the light of the findings from the recent large randomized clinical trials that failed to document a benefit of Hcy lowering on clinical outcome of patients with atherosclerosis, the role of Hcy as a risk factor and the efficacy of Hcy lowering against atherosclerosis have been questioned. Therefore, better understanding of the mechanisms relating Hcy and Hcy-lowering treatment with vascular function and atherogenesis is crucial, to help us understand why clinical trials failed to show a benefit from Hcy-lowering treatment. Are these therapeutic strategies ineffective because they fail to reduce intracellular Hcy levels and vascular redox state or should Hcy stop being considered as an independent risk factor for atherosclerosis from now on? In this review article, we provide a global approach of the molecular mechanisms relating Hcy with cardiovascular risk and introduce possible mechanistic explanations regarding the inability of clinical trials to detect any clinical benefit from Hcy-lowering treatment in secondary prevention. Finally, we provide clinical recommendations regarding the therapeutic strategies targeting homocysteine in the general population.
引用
收藏
页码:6 / 15
页数:10
相关论文
共 83 条
[1]   Is homocysteine a risk factor for atherothrombotic cardiovascular disease? [J].
Akhtar, Naveed .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (12) :1370-1371
[2]  
ANDERSSON A, 1995, CLIN CHEM, V41, P361
[3]  
Antoniades C, 2003, HERZ, V28, P628, DOI 10.1007/s00059-003-2417-8
[4]   Asymmetrical dimethylarginine regulates endothelial function in methionine-induced but not, in chronic homocystinemia in humans: effect of oxidative stress and proinflammatory cytokines [J].
Antoniades, Charalainbos ;
Tousoulis, Dimitris ;
Marinou, Kyriakoula ;
Vasiliadou, Carmen ;
Tentolouris, Costantinos ;
Bouras, George ;
Pitsavos, Christos ;
Stefanadis, Christodoulos .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2006, 84 (04) :781-788
[5]   5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels - Effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling [J].
Antoniades, Charalambos ;
Shirodaria, Cheerag ;
Warrick, Nicholas ;
Cai, Shijie ;
de Bono, Joseph ;
Lee, Justin ;
Leeson, Paul ;
Neubauer, Stefan ;
Ratnatunga, Chandi ;
Pillai, Ravi ;
Refsum, Helga ;
Channon, Keith M. .
CIRCULATION, 2006, 114 (11) :1193-1201
[6]   Hyperhomocysteinemia activates nuclear factor-κB in endothelial cells via oxidative stress [J].
Au-Yeung, KKW ;
Woo, CWH ;
Sung, FL ;
Yip, JCW ;
Siow, YL ;
O, K .
CIRCULATION RESEARCH, 2004, 94 (01) :28-36
[7]   Folic acid fortification and cancer risk [J].
Bayston, R. ;
Russell, Andrew ;
Wald, N. J. ;
Hoffbrand, A. V. .
LANCET, 2007, 370 (9604) :2004-2004
[8]   ELEVATED TOTAL PLASMA HOMOCYSTEINE, A RISK FACTOR FOR THROMBOSIS - RELATION TO COAGULATION AND FIBRINOLYTIC PARAMETERS [J].
BIENVENU, T ;
ANKRI, A ;
CHADEFAUX, B ;
MONTALESCOT, G ;
KAMOUN, P .
THROMBOSIS RESEARCH, 1993, 70 (02) :123-129
[9]   Contribution of whole blood to the control of plasma asymmetrical dimethylarginine [J].
Billecke, Scott S. ;
Kitzmiller, Laura A. ;
Northrup, Joseph J. ;
Whitesall, Steven E. ;
Kimoto, Masumi ;
Hinz, Alia V. ;
D'Alecy, Louis G. .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2006, 291 (04) :H1788-H1796
[10]   Homocysteine lowering and cardiovascular events after acute myocardial infarction [J].
Bonaa, KH ;
Njolstad, I ;
Ueland, PM ;
Schirmer, H ;
Tverdal, A ;
Steigen, T ;
Wang, H ;
Nordrehaug, JE ;
Arnesen, E ;
Rasmussen, K .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (15) :1578-1588